 | 
 | |
Nile Therapeutics, Inc. is a clinical stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease, with an initial focus on heart failure.
Cenderitide
Nile's lead product candidate, cenderitide, is being developed to treat patients following admission for acutely decompensated heart failure (ADHF), an acute exacerbation of heart failure. Patients with ADHF are admitted to the hospital over 1.2 million times per year in the U.S., nearly double the rate recorded 15 years ago. Within 90 days of admission for ADHF, approximately 40% of patients return to the hospital.
Nile believes that the continuous and extended infusion of cenderitide through a subcutaneous pump will provide patients with sustained symptomatic relief in the outpatient setting that could contribute to a reduction in post-acute hospitalizations and persistent improvement in cardio-renal functions.
CU-NP
Nile is also advancing a second drug candidate, CU-NP. This pre-clinical program is evaluating the opportunity for chronic dosing of CU-NP for the potential treatment of a number of cardiovascular and renal diseases.
| |
|
